Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...
What we choose to call cancer may shape patients’ behavior in ways that influence their health outcomes. Relabeling low-grade ...
The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient's ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...
Novel risk stratification tool advances the frontier of precision oncology by providing access to insights informing critical on-the-ground treatment decisions SAN FRANCISCO, August 13, ...
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
Pathologic concordance between prostate biopsy and radical prostatectomy improves with use of a novel robotic-assisted transperineal fusion biopsy platform. Optimization of risk stratification at ...
In April 2021, a provision in the 21st Century Cures act took effect which required that all medical test results be released to a patient's electronic medical record as soon as they become available.
High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results